Management to host investor conference call and webcast at 4:30pm EDT today
PHOENIX, May 18, 2023 (GLOBE NEWSWIRE) — MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), an innovative pharmacy technology company, today announced that the Company will announce financial results for the first quarter ended March 31, 2023, on Thursday, May 18th, after the close of the financial markets. MedAvail management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Call and webcast details:
Thursday, May 18th, 2023 @ 4:30pm ET
Investor dial-in: 1- 877-704-4453 (domestic) or 1-201-389-0920 (international)
Conference ID: 13738987
To access the Call me™ feature, which avoids having to wait for an operator, click here.
The live audio webcast can be accessed by registering online on the “Investor Relations” section of MedAvail’s website at: https://investors.medavail.com. The webcast will be archived and available for replay after the event.
About MedAvail
MedAvail Holdings, Inc. (NASDAQ: MDVL) is a pharmacy technology company, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter. MedAvail helps patients to optimize drug adherence, resulting in better health outcomes. Learn more at www.medavail.com.
Contacts:
Investor Relations
Steven Halper/Caroline Paul
Managing Directors, LifeSci Advisors
ir@medavail.com
SOURCE MedAvail Holdings, Inc.
Company to also highlight advancements in denials and underpayments management and speak to the measurable…
Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…
Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…
Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…